Nls pharmaceutics ag NLSPW.US Overview
NLSPW AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
NLSPW Current Performance
-0.65%
Nls pharmaceutics ag
-1.83%
Avg of Sector
-0.40%
S&P500
NLSPW Key Information
NLSPW Revenue by Segments
Browsing restrictions can be lifted for a fee.
NLSPW Net Income
Browsing restrictions can be lifted for a fee.
NLSPW Cash Flow
Browsing restrictions can be lifted for a fee.
NLSPW Profit Margin
Browsing restrictions can be lifted for a fee.
NLSPW PE Ratio River
Browsing restrictions can be lifted for a fee.
NLSPW Financial Forecast
Browsing restrictions can be lifted for a fee.
NLSPW Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
NLSPW Profile
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Price of NLSPW
NLSPW FAQ
When is NLSPW's latest earnings report released?
The most recent financial report for Nls pharmaceutics ag (NLSPW) covers the period of 2024Q2 and was published on 2024/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NLSPW's short-term business performance and financial health. For the latest updates on NLSPW's earnings releases, visit this page regularly.
How much cash does NLSPW have?
At the end of the period, Nls pharmaceutics ag (NLSPW) held Total Cash and Cash Equivalents of 552.76K, accounting for 0.46 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is NLSPW's EPS continuing to grow?
According to the past four quarterly reports, Nls pharmaceutics ag (NLSPW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of NLSPW?
Nls pharmaceutics ag (NLSPW)'s Free Cash Flow (FCF) for the period is -1.53M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 79.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of NLSPW?
The latest valuation data shows Nls pharmaceutics ag (NLSPW) has a Price-To-Earnings (PE) ratio of -40.43 and a Price/Earnings-To-Growth (PEG) ratio of 0.4. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.